Advances in laboratory testing for thrombophilia

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Johnson, Nicholas V ^a   Khor, Bernard ^a   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DABIGATRAN; HEPARIN; HIRUDIN; HIRULOG; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; RIVAROXABAN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; DNA DETERMINATION; FACTOR XA BASED CLOTTING ASSAY; HUMAN; IMMUNOASSAY; LABORATORY TEST; LIVER DYSFUNCTION; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; RUSSELL VIPER VENOM ASSAY; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; VEIN THROMBOSIS;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD PROTEINS; HEMATOLOGIC TESTS; HUMANS; MUTATION; THROMBOPHILIA;

EID: 84859992064     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23186     Document Type: Article

References (37)

1. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
2. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
3. Jorquera JI, Montoro JM, Fernandez MA, et al. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
4. Trossaert M, Conard J, Horellou MH, et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-522.
5. Shaikh S, Van Cott EM. The effect of Argatroban on activated protein C resistance. Am J Clin Pathol 2009; 131: 828-833.
6. Hillarp A, Baghaei F, Fagerberg B, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011: 9; 133-139.
7. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
8. Saenz AJ, Johnson NV, Van Cott EM. Acquired activated protein C resistance caused by lupus anticoagulants. Am J Clin Pathol 2011; 136: 344-349.
9. Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosis. Blood 2001; 97: 844-849.
10. Van Cott EM. All that glitters is gold? Am J Hematol 2010; 85: 223-224.
11. Khor B, Van Cott EM. Laboratory tests for protein C deficiency. Am J Hematol 2010; 85: 440-442.
12. Cooper PC, Cooper SM, Goodfellow KJ, et al. Evaluation of a new venom-based clotting assay of protein C. Int J Lab Hematol 2008; 30: 437-443.
13. Cooper PC, Siddiq S, Morse C, et al. Marked discrepancy between coagulometric protein C activity assays with the pro-thrombotic protein C Asn2Ile substitution. Int J Lab Hematol 2011; 33: 451-456.
14. Walenga JM, Drenth AF, Mayuga M, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: Effect on coagulation factor testing. Clin Appl Thromb Hemost 2008; 14: 325-331.
15. D'Angelo SV, Mazzola G, Della Valle P, et al. Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays. Thromb Res 1995; 77: 375.
16. Faioni EM, Boyer-Neumann C, Franchi F, et al. Another protein S functional assay is sensitive to resistance to activated protein C. Thromb Haemost 1994; 72: 648.
17. Jennings I, Kitchen S, Cooper P, et al. Sensitivity of functional protein S assays to protein S deficiency: A comparative study of three commercial kits. J Thromb Haemost 2003; 1: 1112.
18. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Clin Lab Med 2009; 29: 339-366.
19. Marlar RA, Gausman JN. Protein S Abnormalities: A diagnostic nightmare. Am J Hematol 2011; 86: 418-421.
20. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85: 947-950.
21. Ungerstedt JS, Schulman S, Egberg N, et al. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99: 2271-2272.
22. Rossi E, Chiusolo P, Za T, et al. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): Demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. Thromb Haemost 2007; 98: 695-697.
23. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
24. Picard V, Prescot I, Scarabin PY, et al. Antithrombin Cambridge II (A384S): Prevalence in patients of the Paris Thrombosis Study (PATHROS). Blood 2007; 110: 2777-2778.
25. Corral J, Hernandez-Espinosa D, Soria JM, et al. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
26. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
27. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
28. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95: 362-372.
29. Szecsi PB, Jorgensen M, Klajnbard A, et al. Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 103: 718-727.
30. Burkman RT, Bell WR, Zacur HA, et al. Oral contraceptives and antithrombin III: Variations by dosage and ABO blood group. Am J Obstet Gynecol 1991; 164: 1453-1460.
31. Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-443.
32. Criado Garcia O, Sanchez-Corral P, Rodriguez de Cordoba S. Isoforms of human C4b-binding protein. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. J Immunol 1995; 155: 4037-4043.
33. Rao AK, Niewiarowski S, Guzzo J, et al. Antithrombin III levels during heparin therapy. Thromb Res 1981; 24: 181-186.
34. Van Cott EM, Ledford-Kraemer M, Meijer P, et al. Protein S: An analysis of the North American specialized coagulation laboratory association proficiency testing. Am J Clin Pathol 2005; 123: 778-785.
35. Baron J, Johnson SM, Ledford-Kraemer MR, et al. Protein C assay performance: An analysis of North American specialized coagulation laboratory proficiency testing results. Am J Clin Pathol, in press.
36. Cunningham MT, Olson JD, Chandler WL, et al. External quality assurance of antithrombin, protein C, and protein S assays: Results of the College of American Pathologists Proficiency Testing Program in Thrombophilia. Arch Pathol Lab Med 2011; 135: 227-232.
37. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: Results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost 2003; 1: 748-753.